135 related articles for article (PubMed ID: 8080718)
1. Novel tumour markers: a diagnostic role in pancreatic cancer?
Roulston JE
Br J Cancer; 1994 Sep; 70(3):389-90. PubMed ID: 8080718
[No Abstract] [Full Text] [Related]
2. [Tumour markers of pancreatic cancer (tumour associated antigens)].
Groblewska M; Mroczko B; Szmitkowski M
Pol Arch Med Wewn; 2005 Jun; 113(6):585-93. PubMed ID: 16454450
[No Abstract] [Full Text] [Related]
3. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1994 Mar; 69(3):562-5. PubMed ID: 8123488
[TBL] [Abstract][Full Text] [Related]
4. Serum CA 242: the search for a valid marker of pancreatic cancer.
Ventrucci M; Ubalducci GM; Cipolla A; Panella MA; Ligabue A
Clin Chem Lab Med; 1998 Mar; 36(3):179-84. PubMed ID: 9589807
[TBL] [Abstract][Full Text] [Related]
5. CA50 as a serum marker for pancreatic carcinoma: comparison with CA19-9.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Eur J Cancer; 1994; 30A(7):1042-3. PubMed ID: 7946572
[No Abstract] [Full Text] [Related]
6. Clinical relevance of tumour markers CA 19-9 and CA-50 in sera from patients with pancreatic duct carcinoma.
Von Rosen A; Linder S; Harmenberg U; Wiechel KL
Surg Oncol; 1992 Apr; 1(2):109-13. PubMed ID: 1341241
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775
[TBL] [Abstract][Full Text] [Related]
8. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
Haglund C; Lundin J; Kuusela P; Roberts PJ
Br J Cancer; 1994 Sep; 70(3):487-92. PubMed ID: 8080735
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of diagnostic value of serum Carbohydrate antigen 199 in pancreatic cancer.
Zhang Y; Jiang L; Song L
Minerva Med; 2016 Feb; 107(1):62-9. PubMed ID: 26824636
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic pitfall; interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction.
Pearce S; Thornes H; Carr D; Tanner A
Gut; 1994 May; 35(5):707-8. PubMed ID: 8200572
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of serological markers in the detection and follow-up of pancreatic adenocarcinoma.
Audisio RA; Veronesi P; Maisonneuve P; Chiappa A; Andreoni B; Bombardieri E; Geraghty JG
Surg Oncol; 1996 Apr; 5(2):49-63. PubMed ID: 8853239
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer.
Kawa S; Tokoo M; Hasebe O; Hayashi K; Imai H; Oguchi H; Kiyosawa K; Furuta S; Homma T
Br J Cancer; 1994 Sep; 70(3):481-6. PubMed ID: 8080734
[TBL] [Abstract][Full Text] [Related]
13. A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patients.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1992; 12(6B):2309-14. PubMed ID: 1295478
[TBL] [Abstract][Full Text] [Related]
14. Application values of detection of serum CA199, CA242 and CA50 in the diagnosis of pancreatic cancer.
Lei XF; Jia SZ; Ye J; Qiao YL; Zhao GM; Li XH; Chang H
J Biol Regul Homeost Agents; 2017; 31(2):383-388. PubMed ID: 28685541
[TBL] [Abstract][Full Text] [Related]
15. Does serum CAR-3 play a role in pancreatic cancer diagnosis?
Basso D; Panozzo MP; Fabris C; Meggiato T; Faggian D; Fogar P; Scalon P; Del Favero G; Plebani M; Burlina A
Oncology; 1991; 48(1):22-5. PubMed ID: 1987495
[TBL] [Abstract][Full Text] [Related]
16. Is CA242 really a new tumour marker for pancreatic adenocarcinoma?
Plebani M; Basso D; Navaglia F; D'Angeli F; Panozzo MP; Del Giudice G; Battistel M; Meggiato T; Del Favero G
Oncology; 1995; 52(1):19-23. PubMed ID: 7800337
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of the serum CA 19-9 test for diagnosing pancreatic carcinoma in symptomatic patients: a prospective study.
Malesci A; Montorsi M; Mariani A; Santambrogio R; Bonato C; Bissi O; Tacconi M; Wizemann G; Spina G
Pancreas; 1992; 7(4):497-502. PubMed ID: 1641392
[TBL] [Abstract][Full Text] [Related]
18. New tumor-associated antigen SC6 in pancreatic cancer.
Liu MP; Guo XZ; Xu JH; Wang D; Li HY; Cui ZM; Zhao JJ; Ren LN
World J Gastroenterol; 2005 Dec; 11(48):7671-5. PubMed ID: 16437697
[TBL] [Abstract][Full Text] [Related]
19. [Use of tumor marker CA50].
Wøldike PM; Charib K; Siboni A
Ugeskr Laeger; 2008 Sep; 170(38):2985; author reply 2986. PubMed ID: 18816889
[No Abstract] [Full Text] [Related]
20. CA 242--a step ahead.
Shahi SK; Ranga S; Bhullar C
Indian J Pathol Microbiol; 2002 Apr; 45(2):145-6. PubMed ID: 12696727
[No Abstract] [Full Text] [Related]
[Next] [New Search]
